Natco Pharma rises after USFDA classifies Hyderabad facility as VAI

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

19 September 2025 13:02:00

Adani Ports

1441.95

(2.10%)

Asian Paints

2508.55

(1.22%)

Axis Bank

1134.55

(0.14%)

Bajaj Finance

991.80

(-0.64%)

Bajaj Finserv

2058.30

(-0.52%)

Bharat Electro..

410.35

(0.12%)

Bharti Airtel

1945.80

(0.20%)

Eternal Ltd

338.25

(0.10%)

HCL Technologi..

1468.50

(-1.69%)

HDFC Bank

964.65

(-1.22%)

Hind. Unilever

2568.00

(-0.72%)

ICICI Bank

1403.55

(-1.29%)

Infosys

1522.40

(-1.16%)

ITC

410.45

(-0.36%)

Kotak Mah. Ban..

2032.15

(-1.07%)

Larsen & Toubr..

3683.10

(-0.11%)

M & M

3628.70

(-0.34%)

Maruti Suzuki

15893.15

(0.47%)

NTPC

338.20

(0.39%)

Power Grid Cor..

287.25

(-0.64%)

Reliance Indus..

1412.90

(-0.12%)

SBI

862.15

(0.90%)

Sun Pharma.Ind..

1661.95

(0.79%)

Tata Motors

710.90

(-0.01%)

Tata Steel

171.60

(-0.23%)

TCS

3157.75

(-0.58%)

Tech Mahindra

1546.85

(-0.23%)

Titan Company

3466.45

(-1.27%)

Trent

5099.80

(-0.87%)

UltraTech Cem.

12556.00

(-0.55%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Natco Pharma rises after USFDA classifies Hyderabad facility as VAI	Share Back
(18 Sep 2025)
In an exchange filing dated 19 June 2025, Natco Pharma said the USFDA inspection was conducted from 9 June to 19 June 2025. Following the inspection, the company received seven observations in the Form-483. The company expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to cGMP compliance and supplying high-quality products to its global customers and patients. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company’s consolidated net profit fell 28.1% to Rs 480.70 crore in Q1 FY26, compared with Rs 668.50 crore in Q1 FY25. Revenue from operations declined 2.5% YoY to Rs 1,328.90 crore in Q1 FY26.
Top